Mariko Nakagomi

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study

Toshitaka Nakamura, Masataka Shiraki, Masao Fukunaga et al. · Osteoporosis International · 2013 · 42 citations

Bone Disease, Bone Health, Medicine +9

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia

Tamio Teramoto, Masayoshi Shirakawa, Masashi Kikuchi et al. · Atherosclerosis · 2013 · 29 citations

Lipid Disorder, Cardiovascular Disease, Medicine +8

Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia

Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki et al. · Atherosclerosis · 2017 · 16 citations · Full text

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia

Hidenori Arai, Tamio Teramoto, Hiroyuki Daida et al. · Atherosclerosis · 2016 · 12 citations

Metabolic Syndrome, Lipid Disorder, Oxysterol +10